Max Briston Pharmaceutical Private Limited
About Max Briston Pharmaceutical Private Limited
Data last updated:
Max Briston Pharmaceutical Private Limited is a private limited company based in Kozhikode, Kerala, India. It operates in the pharmaceutical retail and distribution segment of the pharmaceuticals sector. It was incorporated on 18 August 2015 and has been in existence for over 11 years.
The company is registered with the Registrar of Companies (ROC), Ernakulam, under CIN U24297KL2015PTC039023. Its GSTIN is 32AAKCM0533H1ZT (Kerala).
The company has an authorised share capital of ₹5 Lakh and a paid-up capital of ₹5 Lakh. It is led by directors Sudheer Gangadharan and Sindhu Chittakkudy.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Bharath Towers Near Arya Samajam Rammohan Road P.O. Puthiyara, Kozhikode, Kerala, India – 673004.
As per the financials filed for FY 2024, the company reported a revenue of ₹5.6 Lakh, a decline of 24% compared to the previous year. For the same year it recorded a net profit of ₹10,496 (net margin 1.9%) and EBITDA of -₹79,857 (EBITDA margin -14.3%). Revenue has grown at a compounded annual rate (CAGR) of 9% over three years.
The current compliance status is marked as compliant by the Registrar of Companies.
Company details
Contact details
Max Briston Pharmaceutical Private Limited's registered office is in Kozhikode, Kerala. Its e-mail address is in the company report.
- Email
- Registered AddressBharath Towers Near Arya Samajam Rammohan Road P.O. Puthiyara, Kozhikode, Kerala, India – 673004
- IndustryPharma, Pharmaceutical Retailers & Distributors
To see the full contact details of Max Briston Pharmaceutical Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Max Briston Pharmaceutical is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Max Briston Pharmaceutical Private Limited, buy the company report.
Financials of Max Briston Pharmaceutical Private Limited
FY 2025 filings availableMax Briston Pharmaceutical Private Limited reported revenue of ₹5.6 Lakh (down 24% YoY) for FY 2024.
Compounded Annual Growth Rate (CAGR)
Revenue fell 24% in the latest year, but over three years it has grown at a compounded annual rate (CAGR) of 9%. EBITDA rose 78% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | -₹79,857 | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹10,496 | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | -14.3% | ||||
| Net Profit Margin | 1.9% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Max Briston Pharmaceutical Private Limited, buy the company report.
Board of directors of Max Briston Pharmaceutical Private Limited
Max Briston Pharmaceutical has 2 current directors and 5 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Sudheer Gangadharan | Director | 18 Aug 2015 | 11 Years 2 Months | Current |
| Sindhu Chittakkudy | Director | 05 Apr 2021 | 5 Years 7 Months | Current |
Peer comparison
Max Briston Pharmaceutical Private Limited is compared with the 9 companies closest to it by revenue in the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Sanromo Polymers Private Limited | ₹5.63 Lakh (FY 2025) | -98.0% | Sikandrabad, Uttar Pradesh, India | |||
| Biotech Solution and Agrochemical Private Limited | ₹5.62 Lakh (FY 2024) | 57.0% | Kolkata, West Bengal, India | |||
| Medimerk Pharma Private Limited | ₹5.61 Lakh (FY 2022) | Mumbai, Maharashtra, India | ||||
| Vedkaya Pharmaceuticals Private Limited | ₹5.6 Lakh (FY 2019) | -58.0% | New Delhi, Delhi, India | |||
| Max Briston Pharmaceutical Private Limitedthis company | ₹5.6 Lakh (FY 2024) | ₹10,496 | 1.9% | -24.0% | Kozhikode, Kerala, India | |
| Engrave Bio Labs Private Limited | ₹5.6 Lakh (FY 2025) | -84.0% | Patancheru, Telangana, India | |||
| Cybele Herbal Laboratories Private Limited | ₹5.6 Lakh (FY 2021) | -58.0% | Ernakulam, Kerala, India | |||
| Synthomed Research Private Limited | ₹5.6 Lakh (FY 2024) | Indore, Madhya Pradesh, India | ||||
| Ascetic Pharmaceuticals Private Limited | ₹5.6 Lakh (FY 2018) | -51.0% | Patna, Bihar, India | |||
| Horizon Lifesciences Private Limited | ₹5.59 Lakh (FY 2018) | 14.0% | Boriya, Gujarat, India |
To see the full peer comparison of Max Briston Pharmaceutical Private Limited, buy the company report.
Legal cases
No court or tribunal cases involving Max Briston Pharmaceutical Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Max Briston Pharmaceutical Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Max Briston Pharmaceutical has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 32AAKCM0533H1ZT | Kerala | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Max Briston Pharmaceutical Private Limited, buy the company report.
Recent activity
Max Briston Pharmaceutical Private Limited has 7 board changes on record since 2015: 2 appointments and 5 cessations. The latest: Katayanat Mohanakrishnan ceased to be Director on 05 Apr 2021.
Frequently asked questions
Max Briston Pharmaceutical is an active private limited company based in Kozhikode, Kerala, India. The company works in pharmaceutical retailers and distributors, within the pharma industry. It was incorporated on 18 August 2015 (11+ years old) and is registered under CIN U24297KL2015PTC039023.
Max Briston Pharmaceutical has 2 current directors:
- Sudheer Gangadharan - Director
- Sindhu Chittakkudy - Director
The latest financial statements of Max Briston Pharmaceutical on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from FY 2016 are in the company report.
The GSTIN of Max Briston Pharmaceutical is 32AAKCM0533H1ZT, registered in Kerala.
The CIN (Corporate Identification Number) of Max Briston Pharmaceutical is U24297KL2015PTC039023. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Max Briston Pharmaceutical was incorporated on 18 August 2015, making it 11+ years old. It is registered with the Registrar of Companies, Ernakulam.
The peers of Max Briston Pharmaceutical by revenue are Sanromo Polymers Private Limited, Biotech Solution and Agrochemical Private Limited, Medimerk Pharma Private Limited, Vedkaya Pharmaceuticals Private Limited, Engrave Bio Labs Private Limited and 4 more, all in the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Katayanat Mohanakrishnan ceased to be Director on 05 Apr 2021. Sarath Chandran Sreedharan Nambikeriyil ceased to be Director on 05 Apr 2021. Sindhu Chittakkudy was appointed as Director on 05 Apr 2021. Max Briston Pharmaceutical has 7 board changes on record in total.
The registered office of Max Briston Pharmaceutical is at Bharath Towers Near Arya Samajam Rammohan Road P.O. Puthiyara, Kozhikode, Kerala, India – 673004.
Max Briston Pharmaceutical operates in the pharma industry, in the pharmaceutical retailers and distributors segment.
The compliance status of Max Briston Pharmaceutical is compliant as of 03 September 2026. The company is actively filing with the Registrar of Companies.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
